IOVA Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Chartmill - Mentions: CCOI AMSC ASPN GDEN ...

Top movers in Thursday's session

17 days ago - By: Chartmill - Mentions: CCOI AMSC ASPN GDEN ...

Top stock movements in today's session.

2 days ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 days ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

12 days ago - By: The Motley Fool

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?

16 days ago - By: Zacks Investment Research - Mentions: ALKS ANIP CRMD

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

16 days ago - By: The Motley Fool - Mentions: NTLA

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street

17 days ago - By: Chartmill - Mentions: AMSC ASPN GDEN ELF ...

Gapping stocks in Thursday's session

17 days ago - By: Stocktwits

Why Are IOVA Shares Rising Today?

17 days ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

17 days ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

17 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

18 days ago - By: Zacks Investment Research - Mentions: DVAX

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

18 days ago - By: Benzinga

Examining the Future: Iovance Biotherapeutics's Earnings Outlook

19 days ago - By: Zacks Investment Research - Mentions: STOK

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

20 days ago - By: Zacks Investment Research - Mentions: ARCT

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

20 days ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

20 days ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

25 days ago - By: Bragar Eagel & Squire

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

a month ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

a month ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

a month ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 months ago - By: Bragar Eagel & Squire

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2 months ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 months ago - By: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

3 months ago - By: Iovance Biotherapeutics, Inc.

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock News

IOVA Latest News, Press Relases and Analysis

Top movers in Thursday's session

Top stock movements in today's session.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street

Gapping stocks in Thursday's session

Why Are IOVA Shares Rising Today?

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

Earnings Scheduled For November 6, 2025

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

Examining the Future: Iovance Biotherapeutics's Earnings Outlook

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics to Present at Upcoming Conferences